miltefosine has been researched along with Diseases of Immune System in 1 studies
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral treatment with miltefosine is generally well tolerated and has relatively few adverse effects." | 1.40 | Repurposing miltefosine for the treatment of immune-mediated disease? ( Hommes, DW; Peppelenbosch, MP; van den Brink, GR; Verhaar, AP; Wildenberg, ME, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Verhaar, AP | 1 |
| Wildenberg, ME | 1 |
| Peppelenbosch, MP | 1 |
| Hommes, DW | 1 |
| van den Brink, GR | 1 |
1 other study available for miltefosine and Diseases of Immune System
| Article | Year |
|---|---|
Repurposing miltefosine for the treatment of immune-mediated disease?
Topics: Adaptive Immunity; Adjuvants, Immunologic; Drug Discovery; Humans; Immune System Diseases; Immunity, | 2014 |